Trevi Therapeutics (TRVI) Q2 2025: $204M Cash Secured as Phase III Readiness Accelerates
Trevi Therapeutics enters a pivotal stretch with a $204 million cash position, fresh off strong Phase IIb CORAL and RIVER trial data for chronic cough indications. The company is now focused on aligning with the FDA for Phase III trials in idiopathic pulmonary fibrosis (IPF) and expanding into non-IPF interstitial lung diseases (ILD), targeting a significantly larger patient pool. With operational discipline and a robust clinical pipeline, Trevi’s path to late-stage development and commercial readiness is now a question of execution, not resources.
Summary
- Capital Infusion Extends Runway: Recent $115M raise provides funding into 2029, supporting multiple Phase III trials and commercial prep.
- Strategic Expansion Beyond IPF: Non-IPF ILD program doubles addressable market, leveraging clinical and commercial synergies.
- Phase III Execution in Focus: FDA alignment and data-driven dose selection will determine trajectory through pivotal trials.
Performance Analysis
Trevi’s Q2 2025 results reflect a company transitioning from proof-of-concept to late-stage execution, underpinned by positive data from the CORAL (IPF chronic cough) and RIVER (refractory chronic cough, RCC) trials. The net loss was stable year-over-year, with R&D expenses declining due to the wrap-up of earlier-stage studies, offset by new Phase I work and increased personnel costs. General and administrative (G&A) expenses rose, primarily from higher headcount and professional fees, including internal controls as market cap requirements increase.
The defining financial event was the $115 million capital raise following the CORAL readout, propelling cash and investments to $204 million, which management asserts will fund operations through 2029. This runway covers two pivotal Phase III trials in IPF, a non-IPF ILD cough study, an RCC trial, and pre-commercial activities. The burn rate is expected to remain flat until major trials ramp in 2026, giving Trevi breathing room to focus on clinical and regulatory execution.
- R&D Expense Shift: Lower spend from completed Phase II trials, offset by new Phase I studies and higher personnel costs.
- G&A Inflation: Increased costs tied to scaling for public company compliance and commercial readiness.
- Financial Flexibility: $204M cash position enables parallel advancement of multiple programs without near-term financing risk.
Operational discipline and capital allocation now underpin Trevi’s ability to deliver on late-stage milestones, with the next inflection point hinging on successful FDA engagement and trial initiations.
Executive Commentary
"The first half of this year has been a major inflection point for Trevi, with positive data readouts in both the CORAL trial for chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and the RIVER trial for patients with refractory chronic cough, or RCC. As a result of this strong data, we were able to raise approximately $115 million in capital for total cash and investments at the end of June of approximately $204 million. This gives us strong runway to execute against several important clinical milestones in each of our programs."
Jennifer Good, President and CEO
"Our cash and investment balance gives us cash runway into 2029 and enables us to fund two phase three trials of Haduvio for the treatment of chronic cough in patients with IPF, our planned trial for chronic cough in patients with non-IPF ILD, our next trial in patients with RCC, the phase one work Jennifer discussed, and it enables pre-commercial planning activities. In summary, Trevi is in a strong position financially to execute our business plan."
Lisa Delfini, Chief Financial Officer
Strategic Positioning
1. Phase III Readiness and Regulatory Alignment
Trevi’s immediate priority is securing FDA alignment on its Phase III program for Haduvio, its lead candidate for chronic cough in IPF. The company is leveraging robust CORAL data, with statistically significant improvements in both cough frequency and quality of life (as measured by the Lester Cough Questionnaire, or LCQ, a validated patient-reported outcome tool). The 54 mg BID dose is emerging as the anchor for Phase III, with the end-of-Phase II meeting targeted for Q4 2025. This regulatory milestone will determine the pace and scope of pivotal trials, including requirements for safety database size and long-term exposure data.
2. Expanding Addressable Market with Non-IPF ILD
Trevi is preparing to launch a trial in non-IPF ILD, a heterogeneous group of fibrotic lung diseases that more than doubles the potential market versus IPF alone. These patients are managed by the same pulmonologists, allowing for operational and commercial leverage. The company’s evolving trial design, now favoring a parallel-arm approach, reflects confidence in Haduvio’s mechanism across fibrotic cough etiologies and aims to accelerate the path to label expansion.
3. Best-in-Class Ambition in RCC
In refractory chronic cough (RCC), Trevi is positioning Haduvio for a best-in-class profile, focusing on treatment-resistant patients where unmet need remains high. The upcoming Phase IIb dose-ranging study is set to begin in the first half of 2026, with management undeterred by competitor delays. Strong RIVER data underpins confidence in trial execution and future differentiation.
4. Operational and Commercial Infrastructure Buildout
G&A expense growth signals Trevi’s shift toward commercial readiness, with investment in internal controls, compliance, and pre-launch planning. The company’s strategy is to commercialize directly in the U.S. while exploring partnerships for Europe and Japan, maintaining optionality as pivotal data matures.
Key Considerations
Trevi’s second quarter marks a transition from clinical validation to late-stage execution, with capital, data, and organizational focus converging on pivotal milestones. The company’s ability to manage regulatory complexity, operational scale-up, and market expansion will determine long-term value creation.
Key Considerations:
- Regulatory Pathway Clarity: End-of-Phase II FDA feedback will dictate Phase III trial design, dose selection, and potential NDA-enabling requirements.
- Parallel Program Advancement: Running IPF, non-IPF ILD, and RCC trials in tandem leverages resources but increases operational risk if timelines slip.
- Quality of Life Differentiation: LCQ outcomes are pivotal for both regulatory and reimbursement positioning, supporting a value-based commercial narrative.
- Cash Runway Reduces Dilution Risk: $204M in cash enables execution through multiple clinical catalysts without near-term financing, a rarity among small-cap biotechs.
- Commercial Focus on U.S. Market: Direct commercialization in the U.S. preserves upside, with ex-U.S. partnerships providing optionality.
Risks
Key risks include regulatory uncertainty around Phase III design and endpoints, potential operational delays as multiple trials progress in parallel, and the challenge of translating strong patient-reported outcomes into regulatory and payer acceptance. Competitive dynamics in RCC and non-IPF ILD, as well as the evolving reimbursement landscape for novel cough therapies, also present headwinds. Any setbacks in FDA alignment or trial execution could materially impact timelines and investor confidence.
Forward Outlook
For Q3 and Q4 2025, Trevi guided to:
- Request end-of-Phase II FDA meeting for IPF cough in Q4 2025
- Complete Phase I respiratory safety and drug-drug interaction studies
For full-year 2025, management maintained guidance:
- Cash runway into 2029, supporting all planned clinical and pre-commercial activities
Management emphasized that OPEX will remain steady until Phase III trials begin in 2026, and that key milestones for trial initiations and regulatory alignment will be communicated as achieved.
- FDA feedback will clarify pivotal trial structure
- Non-IPF ILD trial design will be finalized post-agency input
Takeaways
Trevi’s Q2 marks a pivot to late-stage development, with capital and data supporting a multi-pronged clinical strategy.
- Clinical Data Validates Path Forward: Statistically significant improvements in both objective cough frequency and LCQ quality of life drive confidence in Haduvio’s late-stage prospects.
- Operational Readiness Now a Differentiator: Parallel trial execution and commercial buildout require disciplined project management to avoid resource dilution and timeline slippage.
- Investor Focus on Regulatory and Execution Milestones: Next catalysts are FDA alignment, trial initiations, and ongoing data presentations at major medical meetings.
Conclusion
Trevi Therapeutics enters a critical phase with the resources, data, and organizational focus required to pursue late-stage clinical and commercial milestones. The next six to twelve months will test the company’s ability to translate potential into progress as it seeks to expand its addressable market and solidify its leadership in fibrotic cough.
Industry Read-Through
Trevi’s progress highlights the growing focus on patient-reported outcomes and quality of life as differentiators in respiratory drug development. The cash runway and operational discipline stand out in a sector often plagued by financing risk and trial delays. As the cough and pulmonary fibrosis landscape evolves, Trevi’s parallel pursuit of multiple high-need indications and early commercial planning set a template for late-stage biotech strategy. Competitors in chronic cough and ILD will need to match both clinical rigor and operational execution to remain relevant.